Recent Updates
Recently added Catalysts
DARE Positive Sentiment

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Thursday, August 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Daré Bioscience, a biotech company dedicated to women's health, announced its participation in the virtual investor series titled 'Why Now'. The company aims to bridge the gap between scientific advancements and practical solutions for women's health. A video webcast of the event is now available for interested viewers.

Market Sentiment Analysis

POSITIVE FACTORS

  • Daré Bioscience is focused on women's health solutions.
  • Participation in the investor series highlights company engagement.
  • The webcast is now available for broader audience access.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~5 mo
High dilution risk
Lead asset
Lopinavir/ ritonavir
Phase 2 · Human Papilloma Virus (HPV)

Full Press Release Details

Video webcast now available here SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated

Frequently Asked Questions

What is the focus of Daré Bioscience?

Daré Bioscience focuses on closing the gap in women's health through innovative solutions.

Where can I watch the investor series webcast?

The video webcast of the investor series is available online.

Who is the CEO of Daré Bioscience?

The CEO of Daré Bioscience is Sabrina Martucci Johnson.

What was the event Daré Bioscience participated in?

Daré Bioscience participated in the virtual investor series titled 'Why Now'.

ShareAdd on Google
Tags: DARE Viatris Investor Conferences Healthcare Daré Bioscience Sabrina Martucci Johnson women's health investor series NASDAQ: DARE
Last updated: Aug 27, 2026

Biotech snapshot

Cash runway
$13M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
Lopinavir/ ritonavirPhase 2
Human Papilloma Virus (HPV) →